U.S. markets closed

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
73.54-1.50 (-2.00%)
At close: 4:00PM EDT

74.22 +0.68 (0.92%)
After hours: 6:42PM EDT

Sign in to post a message.
  • D
    Didier
    Quite the day. If anyone wonders what a real institution (Blackrock) selling looks like, this was it. Hard to be positive about it, but at least buyers started stepping up at 74 usd, I took the chance to add some as well. Glad the 2017 support levels are holding for now.
    Now, when it comes to the ER.. I don't think the financials need much of an explanation, the small "profit" was mainly due to the Fidelta sale and EUR/USD exchange literally hitting its low at the end of March. Sales and royalty income was rather low, and today during the presentation they said France would also need Manta results before allowing Filgo for men. Management doesn't worry about the outcome of the study, but it doesn't really reinstate the confidence from the investors. Hopefully, Manta will be just fine and sales will follow slowly but surely (obviously they still need to fix reimbursements, but investors are impatient).
    Dropping the trash/filler from their pipeline is a good move in my opinion, but it's easy to see all the things dropped as a waste of money and just another failure. But focusing on just a couple of areas, where they should have plenty of expertise, will be beneficial in the long run. They dropped '1205 in IPF because they felt it was a molecule that would be suited for combination with another drug, not as a "stand-alone", while the chitinase inhibitor showed more promise. Metabolic diseases were dropped because of the "difficulty level", I think it would take too many resources that are better spent in their core area.
    As I mentioned here yesterday, the potential for SIK inhibitors (Toledo) is huge.. But being first means it's also risky and difficult. For the people who like to read, there is some studies to be found online. The analyst from Jefferies stated that a succesful Toledo molecule would reach peak sales of 3b, which is obviously a bit random, since it's so early and PoC studies are still underway with first results only expected this summer..
    Anyway, during the webcast there was another confirmation that they are looking to "fill the gap" between Filgo and the existing pipeline. Both acquiring a late-stage ph2 molecule (together with Gilead?) and getting the commercial rights for the European sales of a product are being looked at. Getting in some revenue instead of sitting on all that cash would be a good move, as long as they are patient while looking for a target and don't overpay or rush things.
    There is some things to look forward to, but all in all I expect a calm year. Hopefully when it comes to share price, we will also find a bottom soon, although cheap shares are also an interesting prospect.
    Personal: Obviously I'm long this stock. In an overpriced market I thought this was an interesting target, because of the cash, the potential and the belief that this is way oversold because it did not live up to the hype. Also, got a biochemistry background which helps. Pretty active here because I'm still building a position since, you know, the catching a falling knife thing. Now, I do not set price targets, because I intend to let this compound for the rest of my life (I'm in my twenties).
    Sorry for the novel, but this board really needs some positives. (I understand the pain if you are sitting on 100+ euro shares..)
  • J
    Julius Caesar - Renaissance
    There are some technical indicators crosses that could push for a major sell off in this stock.
    On another side those who like high risk - medium reward a swing from 61-63 to high 68 could be made.
    Know: it is high risk, because certain lines are crossed that could cause a major sell off.
  • T
    TW
    Immediate sellling into strength. Some people, unfortunately, still want out at any price and I don't think they're all retail. Otherwise, nothing wrong with the ER in relation to expectations.
  • P
    PriceItRight
    Buy rating and PT 110#$%$ at Deutsche Bank
    Bullish
  • P
    PriceItRight
    consolidation period is over, nice push up, volume is everything and it is high, so it means change of trend direction.
    Bullish
  • J
    Julius Caesar - Renaissance
    54-56 euro is likely going to be the next areas of support for this titanic
  • M
    Marie
    Trading below cash, has a whole bunch of programs/partnerships,

    UC a huge market

    Add now below 80, in time $100+
  • K
    Kevin
    Cant wait to get out of this stock
  • T
    TW
    Looks like the market is giving the thumbs down to the AGM.
  • D
    Didier
    No idea where the incredibly weak hands keep coming from, but I'm not selling and neither is Gilead.
  • T
    TW
    The market seems to be saying that current management cannot be trusted to handle 5 billion euro in cash responsibly. Sad day.
  • T
    TW
    A case of buy the rumor sell the fact, no doubt, but that Japan news seems more valuable to me than the market is pricing in. General market jitters perhaps weighing on the price?
  • m
    michael
    Picked up this one on Friday afternoon and bought some more shares today. This is a great stock if you are patient. Lot's of succes everyone!
  • m
    michael
    Interesting buy point. This stocks has huge potential as they 5 billion EUR in cash. There are still several research projects going on and of course they have to do their homework to invest in new research also. Anyway, with so much cash on their balance sheet and their plans to also buy existing research I think their future looks bright.
    Bullish
  • g
    george23
    Week 26 data from the MANTA and MANTA-RAy studies, including primary and key secondary endpoints, will be available by mid-2021 and the parties expect to submit the data to regulatory authorities shortly thereafter. In order to complete their review of filgotinib in RA or other future indications, the FDA has requested up to Week 52 follow-up data for patients who show >50% decrease in semen parameters by Week 26 and do not recover in the ongoing MANTA and MANTA-RAy studies.

    Gilead and Galapagos will continue to investigate the potential for filgotinib to support patients living with Inflammatory Bowel Disease (IBD). Gilead will retain operational responsibility for the current trials in Crohn’s disease while Galapagos will assume operational responsibility for ongoing trials in UC. Filgotinib is currently under review by the European Medicines Agency (EMA) for the treatment of UC and is expected to be submitted to the Japanese Ministry of Health, Labour and Welfare in the first half of 2021. Gilead and Galapagos expect to have further
  • P
    PriceItRight
    Great news on MANTA AND MANTA-RAy studies, we will fly now for sure. This is a catalyst we needed.
  • V
    ValueForAll
    $GLPG , please stay on low-mid 80s at least for a couple more weeks. I need to accumulate more cash to buy at this ridiculous price level.
    Bullish
  • a
    alexander
    Many many moons ago this stock was so promising, until I invested at its peak and it went down hill from there. Hopefully they will work on a new drug in the future with very high potential.
  • T
    TW
    Filgotinib will soon be available on the NHS in the UK as a treatment for ulcerative colitis. The global market for ulcerative colitis treatments is expected to reach 10.25 billion by 2027.